Journal: Journal of cardiovascular pharmacology
Article Title: Tetramethylpyrazine and astragaloside IV synergistically ameliorate left ventricular remodeling and preserve cardiac function in a rat myocardial infarction model.
PMID/MRN: 27676326
Publication Date: 2016-Sep-20
Abstract:
Tetramethylpyrazine (TMP) and astragaloside IV (AGS-IV) are herbal ingredients that have been demonstrated in animal models to limit infarct size and protect cardiomyocytes in the acute phase of myocardial infarction (MI), yet their long-term cardio-protective effects have not been evaluated. In the present study, TMP and/or ASG-IV were administrated to rats for 14 days after MI. Echocardiography revealed that the left ventricular (LV) dimensions and cardiac function was preserved in the MI rats with TMP and ASG-IV treatment, compared to untreated MI rats. Moreover, the LV dimensions and cardiac function in the MI rats with TMP and ASG-IV co-treatment were comparable to the sham-operated rats. In addition, TMP and ASG-IV synergistically inhibited LV fibrosis by attenuating MI-induced collagen deposition and elevation of transforming growth factor ?1. TMP and ASG-IV, alone or in synergy, enhanced angiogenesis in the infarcted myocardium and reduced cardiac hypertrophy of the remote myocardium following MI. Furthermore, TMP and ASG-IV mutually upregulated the expression of Sonic hedgehog (Shh), Smmothened (Smo) and Glioblastoma-2 (Gli2), the receptor and signal transducer of Shh signaling pathway, in the infarcted myocardium. In summary, in the circumstance of the irreversible ischemic injury, the anti-fibrotic and pro-angiogenic properties of TMP and ASG-IV on the non-affected tissues contributes to the cardio-protection in the healing phase post MI, and the cardio-protective effects are likely to be mediated via the Shh pathway.